紫杉醇脂质体联合顺铂治疗非小细胞肺癌的近期疗效及安全性分析

Short-term efficacy and safety analysis of paclitaxel liposome combined with cisplatin in the treatment of non-small cell lung cancer

目的 探讨紫杉醇脂质体联合顺铂治疗非小细胞肺癌(NSCLC)的临床效果及安全性。方法 回顾性分析40例接受化疗治疗的NSCLC患者的临床资料,根据化疗方案的不同分为观察1组和观察2组,每组20例。观察1组患者采用紫杉醇注射液联合顺铂进行化疗,观察2组患者采用紫杉醇脂质体联合顺铂进行化疗。比较两组患者治疗效果,治疗前后肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、鳞状细胞癌抗原(SCC)、细胞角蛋白19片段抗原(CYFRA21-1)]水平,不良反应发生情况。结果 观察1组治疗有效率为55.00%(11/20),观察2组治疗有效率为65.00%(13/20);两组治疗有效率对比差异无统计学意义(P>0.05)。治疗前,两组CEA、CA125、SCC和CYFRA21-1水平比较,差异均无统计学意义(P>0.05);治疗后,两组CEA、CA125、SCC和CYFRA21-1水平均显著低于治疗前,且观察2组CEA(7.13±2.04)μg/L、CA125(42.39±8.22)kU/L、SCC(1.82±0.31)μg/L和CYFRA21-1(6.06±1.48)μg/L均低于观察1组的(10.64±2.82)μg/L、(68.46±15.98)kU/L、(2.47±0.55)μg/L、(7.16±1.52)μg/L,差异有统计学意义(P<0.05)。观察1组不良反应发生率为60.00%(12/20),观察2组不良反应发生率为20.00%(4/20);观察2组不良反应发生率低于观察1组,差异有统计学意义(P<0.05)。结论 紫杉醇脂质体联合顺铂治疗NSCLC患者可以显著降低肿瘤标志物水平,在保障治疗效果的同时减少不良反应的发生,治疗安全性较高,值得推广实施。

Objective To discuss the clinical effect and safety of paclitaxel liposome combined with cisplatin in the treatment of non-small cell lung cancer(NSCLC). Methods A total of 40 patients with NSCLC who received chemotherapy were divided into observation group 1 and observation group 2 according to different chemotherapy regimens, with 20 cases in each group. Patients in observation group 1 were treated with paclitaxel injection combined with cisplatin for chemotherapy, while patients in observation group 2 were treated with paclitaxel liposome combined with cisplatin. Both groups were compared in terms of therapeutic effect, and levels of tumor markers [carcinoembryonic antigen(CEA), carbohydrate antigen 125(CA125), squamous cell carcinoma antigen(SCC), cytokeratin 19 fragment(CYFRA21-1)] before and after treatment, and occurrence of adverse reactions. Results The effective rate of observation group 1 was 55.00%(11/20), and the effective rate of observation group 2 was 65.00%(13/20);there was no statistically significant difference in the effective rate of treatment between the two groups(P>0.05). Before treatment, there was no statistically significant difference in the levels of CEA, CA125, SCC and CYFRA21-1 between the two groups(P>0.05). After treatment, the levels of CEA,CA125, SCC and CYFRA21-1 in the two groups were significantly lower than those before treatment in this group;CEA(7.13±2.04) μg/L, CA125(42.39±8.22) kU/L, SCC(1.82±0.31) μg/L and CYFRA21-1(6.06±1.48) μg/L in observation group 2 were lower than(10.64±2.82) μg/L,(68.46±15.98) kU/L,(2.47±0.55) μg/L,(7.16±1.52) μg/L in observation group 1;all the differences were statistically significant(P<0.05). The incidence of adverse reactions in observation group 1 was 60.00%(12/20), and the incidence of adverse reactions in observation group 2 was 20.00%(4/20);the incidence of adverse reactions in observation group 2 was lower than that in observation group 1, and the difference was statistically significant(P<0.05). Conclusion The treatment of NSCLC patients with paclitaxel liposomes in combination with cisplatin can significantly reduce the level of tumor markers, guarantee the therapeutic effect while reducing the occurrence of adverse reactions, and the treatment safety is high, which is worthy of promotio the implementation.